EP. 1: FDA Approves FoundationOne Liquid CDx for Niraparib/Abiraterone in Aggressive Prostate Cancer
The tissue-based companion diagnostic device was approved for the same therapy and indication in August 2023.
EP. 2: Cosibelimab BLA Resubmitted to FDA for Metastatic cSCC
The manufacturer has resubmitted an application to the FDA for approval of the drug cosibelimab, which is being investigated for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma.
EP. 3: FDA Fast Tracks 225Ac-FL-020 in mCRPC
The FDA has granted fast track designation to 225Ac-FL-020, a promising PSMA-targeting radionuclide drug conjugate for metastatic castration-resistant prostate cancer.